AstraZeneca wades deeper into COVID therapeutics

© Reuters. FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble

LONDON (Reuters) – AstraZeneca (NASDAQ:) has signed a licence agreement with a small UK-based biotech company for a slate of COVID antibody therapies, the Anglo-Swedish pharmaceutical giant said on Tuesday.

The experimental antibody therapies – developed by RK Bio, include those designed to target people with compromised immune systems – such as AstraZeneca’s own antibody cocktail, Evusheld, which is already approved in multiple countries.


Read More   Germany to invest 86 billion euros to upgrade ageing railway network

This website uses cookies. By continuing to use this site, you accept our use of cookies.